Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 33.34 kDa 
• Atom Count: 2049 
• Residue Count: 254 
• Unique protein chains: 1

4BYI

Aurora A kinase bound to a highly selective imidazopyridine inhibitor

• DOI: 10.2210/pdb4BYI/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2013-07-19 Released: 2013-11-20 
• Deposition Author(s): Joshi, A., Kosmopoulou, M., Bayliss, R.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.60 Å
• R-Value Free: 0.253 
• R-Value Work: 0.227 
• R-Value Observed: 0.228 

Literature

Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-B]Pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells.

Bavetsias, V., Faisal, A., Crumpler, S., Brown, N., Kosmopoulou, M., Joshi, A., Atrash, B., Perez-Fuertes, Y., Schmitt, J.A., Boxall, K.J., Burke, R., Sun, C., Avery, S., Bush, K., Henley, A., Raynaud, F.I., Workman, P., Bayliss, R., Linardopoulos, S., Blagg, J.

(2013) J Med Chem 56: 9122

• PubMed: 24195668 
• DOI: 10.1021/jm401115g
• Structures With Same Primary Citation


• PubMed Abstract: 
  

Aurora-A differs from Aurora-B/C at three positions in the ATP-binding pocket (L215, T217, and R220). Exploiting these differences, crystal structures of ligand-Aurora protein interactions formed the basis of a design principle for imidazo[4,5-b]pyridine-derived Aurora-A-selective inhibitors. Guided by a computational modeling approach, appropriate C7-imidazo[4,5-b]pyridine derivatization led to the discovery of highly selective inhibitors, such as compound 28c, of Aurora-A over Aurora-B. In HCT116 human colon carcinoma cells, 28c and 40f inhibited the Aurora-A L215R and R220K mutants with IC50 values similar to those seen for the Aurora-A wild type. However, the Aurora-A T217E mutant was significantly less sensitive to inhibition by 28c and 40f compared to the Aurora-A wild type, suggesting that the T217 residue plays a critical role in governing the observed isoform selectivity for Aurora-A inhibition. These compounds are useful small-molecule chemical tools to further explore the function of Aurora-A in cells.

---

Organizational Affiliation: 

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research , London SM2 5NG, United Kingdom.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
AURORA KINASE A	A	285	Homo sapiens	Mutation(s): 0  Gene Names: AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6 EC: 2.7.11.1
Find proteins for O14965 (Homo sapiens) Go to UniProtKB:  O14965
NIH Common Fund Data Resources
PHAROS  O14965 GTEx  ENSG00000087586

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
FH3	A	(S)-N-((1-(6-chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-3-yl)methyl)acetamide C18 H22 Cl N7 O KLKOJHYRAITDCX-LBPRGKRZSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
FH3	IC50 :  9   nM  PDBBind

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.60 Å
• R-Value Free: 0.253 
• R-Value Work: 0.227 
• R-Value Observed: 0.228 
• Space Group: P 6₁ 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 82.456	α = 90
b = 82.456	β = 90
c = 170.664	γ = 120

Software Package:

Software Name	Purpose
PHENIX	refinement
MOSFLM	data reduction
SCALA	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-07-19 
• Released Date: 2013-11-20 
Deposition Author(s): Joshi, A., Kosmopoulou, M., Bayliss, R.

Revision History 

• Version 1.0: 2013-11-20
  Type: Initial release
  
• Version 1.1: 2013-12-11
  Changes: Database references